StemCells, Inc. Closes Enrollment in Dry AMD Trial

Phase II Clinical Trial to Begin This Year
StemCells, Inc. yesterday announced that, based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study.
Exceeding the company’s expectations, interim results showed a 70 percent reduction in the rate of geographic atrophy (GA) as compared to the control eye and a 65 percent reduction in the rate of GA as compared to the expected natural history of the disease. This was after  a single dose of the company’s proprietary HuCNS-SC® human neural stem cells. In addition to these initial efficacy findings, the Phase I/II trial has also demonstrated a favorable safety profile for HuCNS-SC® as a treatment for dry AMD. Final results are expected to be released mid-2015.
Source: Market Watch

Leave a Reply

Your email address will not be published.